



Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte to Be Featured at the 7th Annual C21 BioVentures

Gaithersburg, MD, May 17, 2005 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced Douglas A. Doerfler, President and CEO, will be presenting at the 7th Annual C21 BioVentures in Monterey, California, Monterey Plaza Hotel & Spa, on Thursday, May 26, 2005, at 11:15AM.

Mr. Doerfler will provide an overview of the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical stage therapeutics company developing both company sponsored and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable developers of ex vivo cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's patented technology accelerates development timelines and reduces risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of serious diseases with unmet needs. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary, infectious and genetic disease, and oncology. MaxCyte's technology utilized in biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-clinical through clinical trials to product manufacturing. Cell-loading technologies are fundamental to cell-based therapeutics, gene therapy, and many biopharmaceutical manufacturing applications. MaxCyte has developed and commercialized the most efficient non-viral, clinical grade, scaleable, GMP-compliant cell-loading technology in the marketplace.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###